What is the recommended treatment for a patient diagnosed with Chlamydia (Chlamydia trachomatis)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 1, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Chlamydia Treatment

First-Line Treatment

For uncomplicated genital chlamydia in non-pregnant adults, treat with either azithromycin 1 g orally as a single dose OR doxycycline 100 mg orally twice daily for 7 days—both achieve 97-98% cure rates and are equally effective. 1, 2, 3

Choosing Between First-Line Options

  • Use azithromycin 1 g single dose when:

    • Compliance with a 7-day regimen is questionable 1, 2
    • Follow-up is unpredictable 1
    • Directly observed therapy is needed 1, 3
    • Treating young adults or populations with erratic health-care-seeking behavior 1
  • Use doxycycline 100 mg twice daily for 7 days when:

    • Cost is a primary concern (doxycycline is significantly less expensive) 2
    • The patient can reliably complete a 7-day course 2
    • You have extensive clinical experience with this regimen 1

Implementation Best Practices

  • Dispense medications on-site when possible and directly observe the first dose to maximize compliance 1, 2, 3
  • Patients must abstain from all sexual intercourse for 7 days after initiating treatment and until all sex partners complete treatment 1, 2, 3

Alternative Treatment Regimens

Use alternative regimens ONLY when first-line options cannot be used due to allergy or intolerance. 1, 2

  • Levofloxacin 500 mg orally once daily for 7 days (88-94% efficacy, but lacks clinical trial validation) 1, 2
  • Ofloxacin 300 mg orally twice daily for 7 days (similar efficacy to first-line agents) 1, 2
  • Erythromycin base 500 mg orally four times daily for 7 days 1, 2, 4
  • Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days 1, 2, 4

Critical caveat: Erythromycin is less efficacious than azithromycin or doxycycline and causes frequent gastrointestinal side effects that reduce compliance—avoid as first-line treatment. 1, 2


Treatment During Pregnancy

Azithromycin 1 g orally as a single dose is the preferred treatment during pregnancy. 1, 2, 3

Alternative Options for Pregnant Patients

  • Amoxicillin 500 mg orally three times daily for 7 days 1, 2, 3
  • Erythromycin base 500 mg orally four times daily for 7 days (if azithromycin cannot be tolerated) 1, 2, 4

Absolute Contraindications in Pregnancy

  • Doxycycline 1, 2, 3
  • Ofloxacin 1, 2
  • Levofloxacin 1, 2
  • All fluoroquinolones 1, 2
  • Erythromycin estolate (causes drug-related hepatotoxicity) 1

Pregnancy-Specific Follow-Up

  • Test-of-cure is mandatory 3-4 weeks after treatment completion in pregnant patients due to potential maternal and neonatal complications 2

Pediatric Dosing

Children ≥8 Years Weighing >45 kg

  • Azithromycin 1 g orally as a single dose OR
  • Doxycycline 100 mg orally twice daily for 7 days 1, 2, 3

Children <45 kg

  • Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days 1, 2, 4

Neonates with Chlamydial Conjunctivitis or Pneumonia (Ages 1-3 Months)

  • Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days (approximately 80% effective; may require a second course) 1, 4
  • Alternative: Azithromycin suspension 20 mg/kg/day orally once daily for 3 days 1

Important: Do NOT use non-culture tests (EIA, DFA) in children due to false-positive results from cross-reaction with other organisms. 1


Partner Management

All sex partners from the preceding 60 days must be evaluated, tested, and empirically treated—even if asymptomatic. 1, 2, 3

  • Treat partners with the same regimen as the index patient 1
  • If last sexual contact was >60 days before diagnosis, treat the most recent partner 1
  • Do NOT wait for partner test results before treating—empiric treatment prevents ongoing transmission and complications 1
  • Failing to treat sex partners leads to reinfection in up to 20% of cases 1

Coinfection Considerations

If gonorrhea is confirmed or prevalence is high (>5%) in your patient population, treat for BOTH infections concurrently: 1, 3

  • Ceftriaxone 250 mg IM single dose PLUS
  • Azithromycin 1 g orally single dose 1, 3

Rationale: Coinfection rates are 20-40% in high-prevalence populations. 1, 3

Additional STI Testing

  • Test all chlamydia patients for gonorrhea, syphilis, and HIV at the initial visit 1

Follow-Up and Retesting

Test-of-Cure

Test-of-cure is NOT recommended for non-pregnant patients treated with recommended regimens who are asymptomatic—cure rates exceed 97%. 1, 2, 3

Perform test-of-cure ONLY if: 1, 2

  • Therapeutic compliance is questionable
  • Symptoms persist after treatment
  • Reinfection is suspected
  • Patient is pregnant (mandatory)

Critical timing: Wait at least 3 weeks after treatment before testing—nucleic acid amplification tests performed earlier can yield false-positive results from dead organisms. 1, 2

Mandatory Reinfection Screening

All women with chlamydia should be retested approximately 3 months after treatment, regardless of whether partners were reportedly treated. 1, 2, 3

  • Reinfection rates reach 39% in some adolescent populations 1, 2
  • Repeat infections carry elevated risk for pelvic inflammatory disease and complications compared to initial infection 1, 2
  • Men may also benefit from retesting at 3 months, though evidence is more limited 1

Treatment Failure Management

If azithromycin fails, switch to doxycycline 100 mg orally twice daily for 7 days. 2

Before Retreating, Verify:

  • Wait at least 3 weeks after initial treatment before confirming treatment failure (avoid false-positives from dead organisms) 2
  • Ensure all sexual partners from the last 60 days were adequately treated 2
  • Rule out reinfection from untreated partners 2

After Retreatment:

  • Patient must abstain from sexual intercourse for 7 complete days after starting new treatment 2
  • Schedule repeat testing 3 months after successful treatment 2

Critical Pitfalls to Avoid

  • Do NOT use erythromycin as first-line treatment—poor compliance from gastrointestinal side effects 1
  • Do NOT perform test-of-cure in asymptomatic patients treated with recommended regimens—wastes resources and may yield false-positives 1
  • Do NOT assume partners were treated—directly verify or use expedited partner therapy 1
  • Do NOT wait for test results if compliance with return visit is uncertain in high-prevalence populations—treat presumptively 1
  • Do NOT retreat based on symptoms alone—document objective signs of urethral inflammation or laboratory evidence of infection 1

References

Guideline

Chlamydia Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Chlamydia Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Chlamydia Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.